Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
Jeffrey E. Rubnitz(St. Jude Children's Research Hospital), Dario Campana(National University of Singapore), Susana C. Raimondi(St. Jude Children's Research Hospital), James R. Downing(St. Jude Children's Research Hospital), Ching‐Hon Pui(St. Jude Children's Research Hospital), Mihaela Onciu(Unknown), Norman J. Lacayo(Lucile Packard Children's Hospital), Elaine Coustan‐Smith(St. Jude Children's Research Hospital), Barbara Degar(Dana-Farber Cancer Institute), Gladstone Airewele(Children's Cancer Center), Soheil Meshinchi(Fred Hutch Cancer Center), W. Paul Bowman(Cook Children's Medical Center), Wing Leung(KK Women's and Children's Hospital), Stanley Pounds(St. Jude Children's Research Hospital), Hiroto Inaba(St. Jude Children's Research Hospital), Bassem I. Razzouk(Peyton Manning Children’s Hospital at St.Vincent), Raul C. Ribeiro(St. Jude Children's Research Hospital), Xueyuan Cao(St. Jude Children's Research Hospital), Gary V. Dahl(Lucile Packard Children's Hospital), Jeffrey W. Taub(Wayne State University)
Cited by 586
Related Papers
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
|Science|1999|11.6k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Treatment of Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2006|2k